neurokinin a(4-10)

Neurokinin A(4-10)(TFA) is an agonist of tachykinin NK2 receptor .

Neurokinin A (4-10) TFA is a tachykinin NK2 receptor agonist [1].

[Lys5,MeLeu9,Nle10]Neurokinin A(4-10) (LMN-NKA), a Neurokinin A analogue, is a selective and potent NK2 receptor (NK2R) agonist with prokinetic activity, making it valuable for researching smooth muscle contractions across various tissues through NK-2 receptor engagement [1][2][3].

[bAla8]-Neurokinin A(4-10) is a neurokinin 2 (NK2) receptor agonist.

Neurokinin A(4-10) TFA(97559-35-8 free base) is a tachykinin NK2 receptor agonist[1].

(β-Ala8)-Neurokinin A (4-10), a neuropeptide, is a potent and selective agonist for the NK-2 tachykinin receptor [1].

(Trp7,β-Ala8)-Neurokinin A (4-10) is a potent neurokinin-3 (NK3) antagonist [1].

[Lys5,Tyr6,mLeu9,Nle10]-Neurokinin A (4-10) (ID 305) is a selective NK2R agonist with an EC50 of 3.7 nM for hNK2R. This compound significantly reduces weight loss in diet-induced obesity (DIO) mouse models and improves Loperamide-induced urinary dysfunction in wild-type mice. It is applicable in the study of neurokinin receptor-mediated diseases such as obesity, insulin resistance, and type 2 diabetes.

LMN-NKA acetate is a modified Neurokinin A (4-10) and selective NK2R (Neurokinin 2 receptor) agonist that induces bladder contraction and urination/defecation in rats, and can be used for studying smooth muscle contraction.